Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16006424 | 0.87 | CCR4 (0.40) | CCR4SSTR4SSTR1NAMPTALKBH5 | |
| SCHEMBL24142870 | 0.85 | BRD4 (0.46) | CCR4SSTR4SSTR1NAMPTBRD4 | |
| SCHEMBL20430021 | 0.85 | CCR4 (0.40) | KEAP1NFE2L2CCR4BRD4CREBBP | |
| SCHEMBL15995704 | 0.84 | KEAP1 (0.41) | KEAP1NFE2L2CCR4BRD4KAT2B | |
| SCHEMBL15886675 | 0.82 | CCR4 (0.39) | KEAP1CCR4BRD4KAT2BSMN1; SMN2 | |
| SCHEMBL24249717 | 0.82 | KEAP1 (0.43) | KEAP1NFE2L2CCR4KAT2BKDM4E | |
| SCHEMBL16157871 | 0.82 | CCR4 (0.37) | CCR4SSTR4SSTR1NAMPTALKBH5 | |
| SCHEMBL16154652 | 0.81 | CCR4 (0.41) | KEAP1CCR4SSTR4BRD4KDM4E | |
| SCHEMBL20430326 | 0.81 | L3MBTL1 (0.45) | KEAP1CCR4BRD4KAT2BKDM4E | |
| SCHEMBL16158035 | 0.80 | KAT2B (0.37) | CCR4SSTR4SSTR1KAT2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2943481-B1 | (HETERO)ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9050344-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | KEAP1 2233/4885NFE2L2 3042/4885CCR4 835/4885 |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | KEAP1 2233/4885NFE2L2 3042/4885CCR4 835/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KEAP1 2091/4885NFE2L2 2943/4885CCR4 895/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | KEAP1 2091/4885NFE2L2 2943/4885CCR4 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.